Remember that week in 2015 when biotech stocks just tanked? Yeah, that was wild. One tweet about drug pricing from a political figure basically triggered a bloodbath across the entire sector. We're talking nearly $40 billion wiped out in a single trading session. The whole thing started with that Daraprim controversy - price jumped from $13.50 to $750 overnight - and then it just spiraled from there with more pharma companies catching heat for aggressive pricing.

I watched the iShares Nasdaq Biotechnology ETF (IBB) get absolutely crushed. Down 6.3% in one day, which hadn't happened in over four years at that point. In just six trading days, the fund had dropped almost 18.5%. The sector went full bear mode, and honestly, that kind of regulatory pressure wasn't going away anytime soon.

Here's the thing though - when a trend like that gets going, some traders saw an opportunity. If you were bearish on biotech stocks and wanted to profit from that downside, inverse ETFs made it pretty straightforward. You didn't need to go through short selling mechanics; you could just buy a product designed to move opposite to the sector.

The most popular choice was ProShares UltraShort Nasdaq Biotechnology (BIS), which gave you 2x inverse exposure to the biotech index. It had solid trading volume, over 650,000 shares daily, and the fund had already gained 47% in those six days as the sector cratered. If you wanted even more aggressive positioning, Direxion Daily S&P Biotech Bear 3x Shares (LABD) offered triple leverage in the opposite direction. That one surged 89% in just a few months after launching. There was also ProShares UltraProShort Nasdaq Biotechnology (ZBIO) for similar 3x inverse exposure, up over 75% in that same week.

Obviously, these instruments aren't for buy-and-hold investors. Inverse ETFs rebalance daily, so they're really only suited for short-term tactical plays. But if you genuinely believed the regulatory headwinds would keep the biotech short trade alive for a while, and you had the risk tolerance for leveraged products, these gave you a structured way to express that view without dealing with traditional short mechanics.

The bigger lesson was that when sentiment shifts hard in a sector like biotech, the tools to profit from that shift - whether through inverse ETFs or other means - become pretty accessible. You just had to understand what you were buying and keep your time horizon realistic.